NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03617731,Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7),https://clinicaltrials.gov/study/NCT03617731,,ACTIVE_NOT_RECRUITING,Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment,NO,Multiple Myeloma,DRUG: Lenalidomide|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Isatuximab,"MRD negativity after induction Treatment (comparison of arms IA and IB), Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5), 18 weeks after start of study treatment|Progression Free Survival (PFS) after second randomization (arms IIA and IIB), Response Evaluation by IMWG criteria, time from 2. randomization to progression or death from any cause whichever comes first, censored after three years of maintenance therapy","to compare the four treatment arms (IA-IIA, IA-IIB, IB-IIA, IB-IIB) regarding Progression free survival (PFS), Response evaluation by IMWG criteria, time from 1. randomization (study inclusion) to progression or death whichever comes first (assessed up to 79 months)|to compare all 4 treatment arms (IA-IIA, IA-IIB, IB-IIA, IB-IIB) regarding overall survival (OS) from time of 1.randomization, survival status, time from randomisation to time of death from any cause (assessed up to 79 months)|Overall survival from second randomization, survival status, time from 2. randomization to time of death from any cause (assessed up to 75 months)|Complete Response (CR) rates after induction therapy, Response Evaluation by IMWG criteria, After induction treatment (18 weeks after start of treatment)|Complete Response (CR) after high dose therapy, Response Evaluation by IMWG criteria, After high dose therapy (9 or 12 months after start of therapy)|Complete Response (CR) during/after maintenance therapy, Response Evaluation by IMWG criteria, During/after maintenance therapy (6 months after start of therapy up to 36 months of maintenance therapy)|MRD negativity after high dose therapy, Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5), After high dose therapy (9 or 12 months after start of therapy)|MRD negativity during and after maintenance therapy, Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5), up to 36 months after start of maintenance therapy|Best response to treatment during the trial, Response evaluation by IMWG criteria, response assessment after 3 months, 4,5 months, 5,5 months, 9 months (if applicable: 3 months later after 2. high dose therapy) subsequently every 3 months during maintenance treatment, up to 48 months after start of study treatment|PFS 2 (PFS after next line of therapy) from 2. randomization, Response evaluation by IMWG criteria, time from 2. randomization to time of overall end of trial (up to 75 months)|Toxicity during induction and maintenance with respect to adverse events of CTC grade >3 (and specific adverse events of CTC grade > 2 as defined in the protocol and serious adverse events, toxicity according CTCAE Version v5.0, : from first administration of study drug until 30 days after last administration of study drug or any drug of the study treatment or upon start of a new subsequent chemotherapy, whichever occurs first|Quality of Life Assessment, EORTC (European Organization of Research and Treatment of Cancer) -QLQC30 Questionnaire to assess the quality of life of cancer patients. Impairment of daily life is asked in 4 scales from ""not at all"" (best) to ""very much"" (worst scale), EORTC-QLQMY20 questionnaire to assess health-related quality of life in patients with multiple myeloma with 4 scales from ""not at all (best scale) to ""very much"" (worst scale); EQ(EuroQol Group)-5D-5L Health questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Additionally a visual analogue scale from 100 (best) to 0 (worst scale) is used to assess the quality of health questionnaires., assessed at baseline, after ca. 4.5 months, 9 months, (additionally after 12 months,if a second high dose therapy is administered) after 12 months of maintenance and at end of study (up to 50 months)|Pharmakokinetic analyses of Isatuximab in induction treatment of patients in Arm IB (selected sites only), Determination of serum concentration of isatuximab at different timepoints before, during and after isatuximab infusion, Up to 18 weeks in induction treatment (C1: D1, before infusion, at end of infusion, 1 h after infusion, C1 D8,15,22,29 before infusion; C2 and 3:D1 before infusion|Pharmakokinetic analyses of Isatuximab in maintenance treatment of patients in Arm IIB (selected sites only), Determination of serum concentration of isatuximab at different timepoints, Up to 9 months (C1: D1, before infusion, at end of infusion, 1 h after infusion, C1 D8,15,22 before infusion, C2 -9, D1: before infusion",,University of Heidelberg Medical Center,,ALL,"ADULT, OLDER_ADULT",PHASE3,662,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GMMG HD7,2018-10-18,2025-05,2027-03,2018-08-06,,2025-03-25,"Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, 52074, Germany|Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bad Saarow, 15526, Germany|Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie), Berlin, 12200, Germany|Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie, Berlin, 12351, Germany|HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie, Berlin, 13125, Germany|Studiengesellschaft Onkologie Bielefeld GbR, Bielefeld, 33604, Germany|Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin, Bielefeld, D-33604, Germany|Medizinische Universitätsklinik, Knappschaftskrankenhaus, Bochum, D-44892, Germany|Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie, Bonn, 53105, Germany|Johanniter Krankenhaus Bonn, Bonn, 53113, Germany|Zentrum für ambulante Hämatologie und Onkologie (ZAHO), Bonn, 53113, Germany|Städtisches Klinikum Braunschweig, Med. Klinik III, Hämatologie und Onkologie, Braunschweig, 38114, Germany|Klinikum Chemnitz GmbH, Innere Medizin III, Chemnitz, D-09116, Germany|Carl-Thiem-Klinikum Cottbus gGmbH, II. Medizinische Klinik, Cottbus, 03048, Germany|Onkologisches Studienzentrum Darmstadt, Darmstadt, 64283, Germany|Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie, Darmstadt, D-64283, Germany|Universitätsklinikum Carl Gustav Carus Dresden, an der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, 01307, Germany|HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf, Duisburg, 47166, Germany|Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatologie und Palliativmedizin, Düsseldorf, 40479, Germany|Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie, Düsseldorf, D-40225, Germany|Universitätsklinik Erlangen, Erlangen, 91054, Germany|St. Antonius-Hospital Eschweiler, Klinik für Hämatologie / Onkologie, Eschweiler, 52249, Germany|Universitätsklinikum Essen, Klinik für Hämatologie, Essen, D-45147, Germany|Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation, Essen, D-45239, Germany|Gemeinschaftspraxis Prof. Dr. Michael Kiehl und Dipl. Med. Wolfgang Stein, Frankfurt (Oder), 15236, Germany|Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), 15236, Germany|Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, 60389, Germany|Agaplesion Markus Krankenhaus, Med. Klinik I, Frankfurt am Main, 60431, Germany|Krankenhaus Nordwest, Institut für Klinisch-Onkologische Forschung, Frankfurt am Main, 60488, Germany|Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II, Frankfurt am Main, 60590, Germany|Klinikum Fulda, Klinisches Studienzentrum GmbH, Fulda, 36043, Germany|Universitätsklinik der Justus-Liebig-Universität, Medizinische Klinik IV, Gießen, 35385, Germany|Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital Goch, Klinik für Hämatologie - Onkologie, Goch, 47574, Germany|Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie, Hagen, D-58095, Germany|Asklepios Klinik Hamburg St. Georg, Hamburg, 20099, Germany|Universitätsklinikum Hamburg Eppendorf, Zentrum für Onkologie, Studienzentrale der II. Medizinischen Klinik, Hamburg, 20246, Germany|Asklepios Klinik Hamburg Altona, II. Med. Klinik, Hamburg, D-22763, Germany|Immunologisch-onkologisches MVZ am Siloah Krankenhaus, Hannover, 30449, Germany|KRH Klinikum Siloah, Klinik für Hämatologie und Onkologie, Hannover, 30459, Germany|Onkologische Schwerpunktpraxis Heidelberg, Heidelberg, 69115, Germany|Krankenhaus St. Vincentius der evangelischen Stadtmission Heidelberg, Abt. Hämatologie, Onkologie, Rheumatologie, Heidelberg, 69117, Germany|University Hospital Heidelberg, Med. Klinik V, Heidelberg, D-69120, Germany|SLK Kliniken Heilbronn, Med. Klinik III, Heilbronn, D-74078, Germany|Marien Hospital Herne, Herne, 44625, Germany|Universitätsklinikum des Saarlandes, Innere Medizin I, Homburg (Saar), 66421, Germany|Westpfalz-Klinikum GmbH, Klinik für Innere Medizin I, Kaiserslautern, 67655, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, 76133, Germany|Praxisklinik für Hämatologie und Onkologie, Koblenz, D-56068, Germany|Uniklinik Köln, Klinik I für Innere Medizin, Köln, 50937, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie am Caritas Krankenhaus, Lebach, 66822, Germany|Universitätsklinikum Leipzig AöR, Medizinische Klinik und Poliklinik I-Hämatologie und Zelltherapie, Internistische Onkologie, Hämostaseologie, Leipzig, 04103, Germany|Med. Klinik A, Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen am Rhein, 67063, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, III. Med. Klinik, Mainz, D-55131, Germany|III. Medizinische Klinik Hämatologie und Internistische Onkologie, Mannheim, 68167, Germany|Mannheimer Onkologie Praxis, Mannheim, D-68161, Germany|Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie, Marburg, 35032, Germany|Mühlenkreiskliniken (AöR) Johannes Wesling Klinikum Minden, Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin, Minden, 32429, Germany|Krankenhaus Maria Hilf GmbH, Franziskuskrankenhaus, Med. Klinik I, Mönchengladbach, D-41063, Germany|Universitätsklinikum Münster, Med. Klinik A, Münster, 48149, Germany|Klinikum Osnabrück GmbH, Osnabrück, 49076, Germany|Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie, Paderborn, 33098, Germany|Krankenhaus Barmherzige Brüder, Klinik für Onkologie und Hämatologie, Regensburg, 93049, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Onkologisches Zentrum, Saarlouis, 66740, Germany|Diakonie-Klinikum Schwäbisch Hall gGmbH, Innere Medizin III, Schwäbisch Hall, 74523, Germany|ZAHO-Zentrum für ambulante Hämatologie und Onkologie, Standort Siegburg, Siegburg, D-53721, Germany|Onkologische Schwerpunktpraxis Speyer, Speyer, D-67346, Germany|Klinikum Stuttgart, Stuttgart Cancer Center, Tumorzentrum Eva Mayr-Stihl, Stuttgart, 70174, Germany|Klinikum Mutterhaus der Borromäerinnen gGmbH, Trier, 54290, Germany|University Hospital Tübingen, Med. Klinik und Poliklinik, Abt. II, Tübingen, D-72076, Germany|Bundeswehrkrankenhaus Ulm, Abteilung Innere Medizin - Hämatologie und internistische Onkologie, Ulm, 89081, Germany|Schwarzwald-Baar Klinikum, Innere Medizin II, Villingen-Schwenningen, 78052, Germany|Rems-Murr-Kliniken gGmbH, Winnenden, 71364, Germany",
